• Pharmacological Complementation Remedies an Inborn Error of Lipid Metabolism.

Pharmacological Complementation Remedies an Inborn Error of Lipid Metabolism.

Cell chemical biology (2020-03-15)
Meredith D Hartley, Mitra D Shokat, Margaret J DeBell, Tania Banerji, Lisa L Kirkemo, Thomas S Scanlan

X-linked adrenoleukodystrophy (X-ALD) is a rare, genetic disease in which increased very long chain fatty acids (VLCFAs) in the central nervous system (CNS) cause demyelination and axonopathy, leading to neurological deficits. Sobetirome, a potent thyroid hormone agonist, has been shown to lower VLCFAs in the periphery and CNS. In this study, two pharmacological strategies for enhancing the effects of sobetirome were tested in Abcd1 KO mice, a murine model with the same inborn error of metabolism as X-ALD patients. First, a sobetirome prodrug (Sob-AM2) with increased CNS penetration lowered CNS VLCFAs more potently than sobetirome and was better tolerated with reduced peripheral exposure. Second, co-administration of thyroid hormone with sobetirome enhanced VLCFA lowering in the periphery but did not produce greater lowering in the CNS. These data support the conclusion that CNS VLCFA lowering in Abcd1 knockout mice is limited by a mechanistic threshold related to slow lipid turnover.

Product Number
Product Description

3,3′,5-Triiodo-L-thyronine, ≥95% (HPLC), powder
Lignoceric acid, ≥99% (GC)
L-Thyroxine, ≥98% (HPLC)
Hexacosanoic acid, ≥95% (capillary GC)
Behenic acid, 99%
RNAlater®, Stabilize and protect RNA with immediate RNase inactivation